Ocular Therapeutix (OCUL) Accounts Payables (2013 - 2026)

Ocular Therapeutix's Accounts Payables history runs 14 years deep, the most recent figure standing at $8.0 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 73.5% year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $8.0 million (up 73.5% YoY), while the FY2025 annual figure was $4.2 million, down 0.53% from the prior year.
• Accounts Payables was $8.0 million for Q1 2026 at Ocular Therapeutix, up from $4.2 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $8.0 million in Q1 2026 to a low of $3.4 million in Q1 2022.
• Historically, Accounts Payables has averaged $4.8 million across 5 years, with a median of $4.4 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Accounts Payables slipped 28.31% in 2025, then surged 73.5% in 2026.
• A 5-year view of Accounts Payables shows it stood at $5.1 million in 2022, then decreased by 14.33% to $4.4 million in 2023, then declined by 4.85% to $4.2 million in 2024, then retreated by 0.53% to $4.2 million in 2025, then surged by 93.21% to $8.0 million in 2026.
• The last three Accounts Payables figures came in at $8.0 million (Q1 2026), $4.2 million (Q4 2025), and $6.3 million (Q3 2025), per Business Quant data.